Three Toronto high-tech companies receive seed funding through Ontario’s Investment Accelerator Fund (IAF): Geminare Inc, MedCurrent Corporation and Receptor Therapeutics.
MaRS is a Toronto-based charitable organization that provides resources – people, programs, physical facilities, funding and networks – to ensure that critical innovation happens. With the mission of removing barriers between innovative medical & technology businesses and Toronto’s annual science and technology research spend, the IAF helps accelerate the growth of Ontario’s new technology companies that have the potential to be global leaders in their field and provide sustainable economic benefits to Ontario.
For Geminare, the investment is key to developing its partner network worldwide. “Geminare’s products are delivered though a network of channel partners to the SME market worldwide,” said Joshua Geist, CEO & Founder, Geminare Inc. “With the help of the IAF investment, Geminare has been able to accelerate its partner program and continue building game-changing Cloud technologies to meet the growing demand for simple and affordable alternatives to traditional in-house business continuity and disaster recovery solution models.”